---
schema_version: "secwatch.filing_event.v1"
accession: "0001753926-26-001144"
form_type: "8-K"
ticker: "VANI"
cik: "0001266806"
company_name: "Vivani Medical, Inc."
filed_at: "2026-07-07T11:46:22+00:00"
generated_at: "2026-07-07T11:50:06.952991+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Vivani subsidiary Cortigent to merge into ClearOne in stock deal; Novo Nordisk to evaluate semaglutide implant

## Summary
- Cortigent (Vivani subsidiary) to merge into ClearOne (Nasdaq: CLRO) for 12.5M ClearOne shares; Vivani will control combined board.
- ClearOne to raise $10M-$15M via unit offering as condition to close; closing expected by Dec 28, 2026.
- Vivani enters non-exclusive agreement with Novo Nordisk to evaluate NPM-139 semaglutide implant for chronic weight management.
- Phase 1 first-in-human study of NPM-139 expected mid-2026 with Wegovy as active comparator.
- Lock-up: 50% of Vivani's ClearOne shares locked 1 year, 50% locked 2 years.

## SEC filing metadata
- accession: 0001753926-26-001144
- form_type: 8-K
- ticker: VANI
- cik: 0001266806
- company_name: Vivani Medical, Inc.
- filed_at: 2026-07-07T11:46:22+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1266806/000175392626001144/0001753926-26-001144-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1266806/000175392626001144/vani-20260701.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001753926-26-001144
- JSON: https://secwatch.observer/filing/0001753926-26-001144.json
- Plain text: https://secwatch.observer/filing/0001753926-26-001144.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.